|2.||Hydatidiform Mole (Molar Pregnancy)
|3.||Invasive Hydatidiform Mole (Invasive Mole)
|4.||Trophoblastic Neoplasms (Trophoblastic Tumor)
|1.||Berkowitz, Ross S: 12 articles (06/2014 - 05/2002)|
|2.||Cheung, Annie N Y: 12 articles (01/2014 - 07/2003)|
|3.||Ngan, Hextan Y S: 10 articles (06/2012 - 07/2003)|
|4.||Seckl, Michael J: 9 articles (11/2014 - 06/2002)|
|5.||Seckl, M J: 9 articles (05/2013 - 07/2000)|
|6.||Sebire, N J: 9 articles (11/2012 - 12/2001)|
|7.||Thomas, Chris M G: 8 articles (06/2014 - 10/2005)|
|8.||Fisher, R A: 8 articles (05/2013 - 07/2000)|
|9.||Hui, Pei: 7 articles (09/2014 - 03/2008)|
|10.||Murphy, Kathleen M: 7 articles (02/2014 - 09/2009)|
|1.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric
07/01/2009 - "Six patients, 5 with complete and 1 with partial hydatidiform mole, had good outcome and normalization of beta-human chorionic gonadotropin (beta-hCG) levels within 5-7 weeks of evacuation. "
01/01/1989 - "Examining the level of SP1 after evacuation of hydatidiform mole it was established that SP1 was eliminated more quickly than human chorionic gonadotropin (HCG) in urine during early pregnancy. "
03/01/2008 - "The objective of the present study was to assess the diagnostic potential of serum human chorionic gonadotropin (hCG) ratios obtained at different intervals after evacuation of hydatidiform mole to diagnose persistent trophoblastic disease (PTD) and to compare its diagnostic accuracy with the current FIGO 2000 criteria as a gold standard. "
05/01/2005 - "Our results support the suggestion that a single undetectable human chorionic gonadotropin level after evacuation is sufficient follow-up to ensure remission in patients with partial hydatidiform moles."
08/01/1986 - "Serum samples, taken at initial diagnosis from nine patients with hydatidiform mole and spontaneous remission and 12 patients with subsequent progression to persistent trophoblastic disease, were assayed for free and total levels of the beta-subunit of human chorionic gonadotropin. "
|2.||DNA (Deoxyribonucleic Acid)IBA
01/01/1991 - "By providing valuable DNA ploidy data, flow cytometric studies of hydatidiform moles may be helpful in the identification of patients at high risk of postmolar trophoblastic sequelae."
01/01/2014 - "STR DNA genotyping is effective for diagnostic measure to precisely classify hydatidiform moles. "
01/01/2014 - "To evacuate whether short-tandem-repeat (STR) DNA genotyping is effective for diagnostic measure to precisely classify hydatidiform moles. "
05/01/2013 - "Histologic diagnosis of partial hydatidiform mole (PHM) continues to be problematic, and DNA genotyping has recently become cost-effective for precise separation of PHM from its mimics. "
04/01/2010 - "To estimate whether tissue DNA genotyping is effective for the confirmation and subclassification of hydatidiform moles. "
03/01/2006 - "Controversy exists regarding the use of oral contraceptives following hydatidiform mole and possible increased risk of persistent trophoblastic neoplasia. "
06/01/2002 - "Clinical reports suggested that the use of oral contraceptives (OC) after a molar pregnancy may increase the risk of persistent throphoblastic disease. "
06/01/1982 - "It has been associated with hydatid mole and the use of oral contraceptives. "
04/01/1989 - "We conclude that oral contraceptives are the preferred method of contraception after evacuation of a hydatidiform mole."
04/01/1989 - "Between 1981 and 1988, 266 patients were randomly assigned to either oral contraceptives or barrier contraception after evacuation of a hydatidiform mole. "
|4.||Messenger RNA (mRNA)IBA
09/01/2008 - "A significant reduction in SOX2 messenger RNA expression was found in the hydatidiform moles (P = .027) when compared with that in the placentas. "
01/01/2001 - "In the hydatidiform mole cases with subsequent spontaneous remission, nm23-H1 mRNA levels were significantly lower than those in first-trimester placentas. "
06/01/2008 - "By quantitative TaqMan real-time PCR, Oct4 mRNA was significantly reduced in hydatidiform moles (P=0.04), JEG3 and JAR (P=0.024) when compared with normal placentas. "
04/01/2003 - "Our results showed significantly lower expression of OPN mRNA and protein in hydatidiform mole, and in particular complete mole (P = 0.001 by real-time PCR and P < 0.001 by immunohistochemistry) as compared to nermal placenta. "
04/01/2003 - "Our purpose was to determine the expression of OPN mRNA and protein in hydatidiform mole and in normal placenta of comparable gestational age. "
|5.||Dactinomycin (Ac-De)FDA LinkGeneric
08/01/2006 - "To evaluate the efficacy of a single prophylactic dose of actinomycin D (Act-D) in the reduction of postmolar gestational trophoblastic neoplasia (GTN) in adolescents with high-risk hydatidiform mole (Hr-HM). "
08/01/2009 - "Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment."
08/01/2006 - "Single-dose actinomycin D: Efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole."
02/01/2001 - "Prophylactic actinomycin D for high-risk complete hydatidiform mole."
08/01/2009 - "To evaluate the efficacy of actinomycin D (Act-D) as prophylactic chemotherapy (P-Chem) to reduce postmolar gestational trophoblastic neoplasia (GTN) in patients with high-risk hydatidiform mole (Hr-HM). "
|6.||Gestational trophoblastic diseaseIBA
01/01/2013 - "Previous studies indicate that epigenetic modifications play an important role in transcriptional regulation and contribute to the pathogenesis of gestational trophoblastic disease, including complete hydatidiform moles (CHMs). "
07/01/2010 - "In the present study, we evaluated the incidence of postmolar gestational trophoblastic disease (GTD) in molar pregnancy. "
05/01/2002 - "Common protocols for managing persistent gestational trophoblastic disease are being derived, and molecular genetic studies are advancing our understanding of molar pregnancy and its sequelae. "
03/01/2001 - "The objective of this study was to assess apoptotic activity in gestational trophoblastic disease (GTD) and its prognostic value in hydatidiform mole (HM). "
09/01/2000 - "The aim of this study was to examine the incidence and characteristics of women who develop a second molar pregnancy after a previous episode of gestational trophoblastic disease. "
|7.||Estrogens (Estrogen)FDA Link
08/01/1964 - "STUDY OF ESTROGEN PRODUCTION IN WOMEN WITH HYDATIDIFORM MOLE."
04/01/1964 - "[STUDIES ON URINARY ESTROGEN EXCRETION AFTER SURGERY OF HYDATIDIFORM MOLE AND DESTRUCTIVE MOLE]."
08/01/1966 - "Formation of estrogens by hydatidiform moles in vitro."
07/23/1966 - "[The formation of estrogens in the hydatidiform mole]."
09/15/1963 - "ABNORMAL URINARY ESTROGEN LEVELS IN HYDATIDIFORM MOLES DETERMINED BY GAS-LIQUID CHROMATOGRAPHY."
06/01/1971 - "Studies of several aspects of thyroid hormone economy have been conducted in 11 patients before and after removal of a molar pregnancy. "
07/01/2013 - "Patients diagnosed with a hydropic abortus do not require hormone surveillance or abstinence from pregnancy for the extended time period generally recommended for patients diagnosed with a complete or partial hydatidiform mole. "
09/01/2005 - "The incidence of HG is approximately 0.5% of live births, said to be higher in multiple pregnancies, hydatidiform mole and other conditions associated with increased pregnancy hormone levels. "
02/01/1998 - "A negative correlation was found between PRL level and all the hormones in normal pregnancy, with the exception of TSH, and in molar pregnancy there was a positive correlation of PRL with all hormones. "
03/01/1988 - "Finally we studied a patient with a molar pregnancy in whom thresholds for hormone release and thirst were both decreased to values resembling normal gestation and remained so for approximately 6 wk postevacuation, only normalizing when hCG had virtually disappeared from her serum. "
|9.||Macrophage Colony-Stimulating FactorIBA
03/01/1994 - "M-CSF promotes the growth of early gestation chorionic cells, hydatidiform mole cells, and a human term placenta cell line (tPA30-1). "
03/01/1994 - "In the present study, we examined whether or not macrophage colony-stimulating factor (M-CSF; CSF-1) is involved in the growth and differentiation of human chorionic, hydatidiform mole and choriocarcinoma cells. "
03/01/1994 - "These results suggest that the growth and differentiation of normal chorionic and hydatidiform mole cells are M-CSF-dependent, while the growth and differentiation of choriocarcinoma cells are not."
03/01/1994 - "When M-CSF localization was examined by immunohistochemical staining, M-CSF was detected in chorionic and hydatidiform mole cells, but was absent in choriocarcinoma cells. "
03/01/1994 - "Macrophage colony-stimulating factor induces the growth and differentiation of normal pregnancy human cytotrophoblast cells and hydatidiform moles but does not induce the growth and differentiation of choriocarcinoma cells."
|10.||Methotrexate (Mexate)FDA LinkGeneric
12/01/2011 - "Our objective was to investigate the impact of two common functional MTHFR polymorphisms, 677C>T and 1298A>C, on the efficacy of methotrexate in women treated for GTN following a molar pregnancy. "
11/20/2012 - "For patients treated with single-agent methotrexate, the primary cure rate ranged from 75% for a FIGO score of 0-1 through to 31% for those with a FIGO score of 6. In the setting of a formal follow-up programme, the expected cure rate for GTT after a molar pregnancy should be 100%. "
12/01/2011 - "Approximately one third of patients treated with methotrexate for gestational trophoblastic neoplasia (GTN) following a molar pregnancy are reported to develop resistance to methotrexate and need to change to different chemotherapeutic agents. "
03/01/2010 - "Systemic methotrexate therapy was administered to treat the possible remnants of the molar pregnancy. "
08/01/1992 - "Two patients with persistent partial molar pregnancy were successfully treated with oral methotrexate therapy. "
|1.||Drug Therapy (Chemotherapy)
06/01/2001 - "Among 1052 patients with molar pregnancy (complete mole, 801; partial mole, 251) monitored at Chiba University Hospital between 1981 and 1999, 891 patients (84.7%) had spontaneous resolution of human chorionic gonadotrophin (HCG) after mole evacuation, and 161 patients (15.3%) required chemotherapy. "
09/01/2007 - "To test the efficacy of a new scoring system to differentiate high-risk hydatidiform mole (H-mole) and initiate early selective postmolar chemotherapy. "
09/01/1987 - "Prophylactic chemotherapy may be useful in the management of high-risk molar pregnancy, especially when hormonal follow-up is either unavailable or unreliable. "
06/01/2001 - "Among the 54 patients who were examined with a diagnosis of complete hydatidiform mole, persistent trophoblastic disease requiring postevacuation chemotherapy developed in 6. In the remaining 48 patients, spontaneous remission of the disease occurred after uterine evacuation. "
01/01/2015 - "Many studies showed that prophylactic chemotherapy for high risk hydatidiform moles could significantly decrease the incidence of malignancy. "
|2.||Contraception (Birth Control)
04/01/1989 - "Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study)"
10/01/2009 - "Evidence shows that postmolar trophoblastic disease risk does not increase among women using COCs or an IUD following molar pregnancy evacuation compared with use of other contraceptive methods or no method."
05/01/1988 - "With the advent of newer diagnostic methods which aid in the early diagnosis of pregnancy and help to differentiate it from abnormal pregnancy together with the increasing concern over the safety of use of the contraceptive measures following a hydatidiform mole, it is suggested that a period of postmolar contraception may no longer be necessary. "
10/01/1981 - "One hundred patients, managed for molar pregnancy at the New England Trophoblastic Disease Center, were selected at random to determine if the contraceptive method following molar evacuation influenced the incidence of postmolar trophoblastic disease. "
05/01/1981 - "[Hormonal contraception after evacuation of hydatid mole (author's transl)]."
12/01/2015 - "Diagnostic curettage revealed hydatidiform mole. "
11/01/2015 - "Hydatidiform mole is treated with surgical uterine evacuation with suction and blunt curettage (D). "
01/01/2014 - "A molar pregnancy was suspected and curettage was performed. "
06/01/2012 - "[Frequency of hydatidiform mole in tissue obtained by curettage]."
01/01/2012 - "We analyzed the immunoreactivity of RCAS1 on both trophoblast and decidual cells derived from patients who underwent curettage because of hydatidiform mole. "
|4.||Vacuum Curettage (Vacuum Pump)
04/01/1999 - "All patients with partial hydatidiform mole had spontaneous remission after vacuum aspiration. "
03/01/2014 - "Urine qualitative hCG was negative and serum quantitative hCG was 1,094,950 mIU/mL. Pelvic ultrasonography showed a uterine cavity containing a soft-tissue mass with multiple cystic lesions and the hydatidiform mole was extracted with suction curettage. "
08/01/2008 - "To determine intrauterine pathology in patients with postmolar gestational trophoblastic neoplasia (GTN) and hydatidiform mole after suction curettage. "
06/01/2007 - "Suction curettage was performed after delivery for removal of the molar pregnancy. "
12/01/2006 - "A 31-year-old, gravida 8, para 1, female patient underwent suction curettage for a diagnosis of molar pregnancy. "
|5.||Intrauterine Devices (Intrauterine Device)
08/01/1986 - "The intrauterine contraceptive device and hydatidiform mole: a negative association."
01/01/2000 - "In a prospective, simple randomised study, we evaluated the relative efficacy of hormonal (oral contraceptive pill) and non-hormonal (intrauterine contraceptive device) methods of contraception as fertility regulatory agents in patients with complete hydatidiform moles and assessed the development of complications and sequelae if any, following their use. "
11/01/1975 - "Certain conditions lend themselves to diagnosis with ultrasound: hydatidiform mole, intrauterine pregnancy, dermoid cyst, ascites, simple ovarian cyst, and lost intrauterine contraceptive devices (IUCD's). "
06/01/1983 - " Discussion focuses on methods, instrumentation, method for examination (grasping the instrument, setup, light source, anesthesia, dilatation, technique, and normal endometrium); cervical neoplasia; nonneoplastic lesions of the endometrium (endometrial polyp, submucous myoma, endometrial hyperplasia); intrauterine device localization; neoplastic lesions of the endometrium; precursors (adenocarcinoma); hysteroscopy in pregnancy (embryoscopy, hydatidiform mole, postpartum hemorrhage, incomplete abortion, spontaneous abortion, induced abortions, and amnioscopy); and examinations of children and infants. "
01/15/1983 - "Relationship of oral contraceptives and the intrauterine contraceptive devices to the regression of concentrations of the beta subunit of human chorionic gonadotropin and invasive complications after molar pregnancy."